Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Michael S. Hofman
ResearcherPublications, citations & collaboration network
Michael S. Hofman is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 535 works, 27,336 citations, an h-index of 81 and an i10-index of 253.
535
Works
27,336
Citations
81
h-index
253
i10-index
How has Michael S. Hofman's publication output changed over time?
ScholarIQpublication output · 2015–2024
Output grew0% over the shown period — from 1 works in 2015 to 1 in 2024.
1
1
2
2
2
3
1
2015201620182019202020212024
What are the most-cited papers on Michael S. Hofman?
ScholarIQmost cited works
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, Colin Tang, Ian Vela, Paul Thomas, Natalie Rutherford, Jarad Martin, Mark Frydenberg, Ramdave Shakher, Lih‐Ming Wong, Kim Taubman, Sze Ting Lee, Edward Hsiao, Paul Roach, Michelle Nottage, Ian Kirkwood, Dickon Hayne, Emma Link, Petra Marušić, A Matera, Alan Herschtal, Amir Iravani, Rodney J. Hicks, Scott Williams, Declan G. Murphy
The Lancet. 20202,004 Citations
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman, John Violet, Rodney J. Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G. Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott Williams, Shahneen Sandhu
The Lancet Oncology. 20181,163 Citations
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang
The Lancet. 20211,112 Citations
Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis
Marlon Perera, Nathan Papa, Daniel Christidis, David Wetherell, Michael S. Hofman, Declan G. Murphy, Damien Bolton, Nathan Lawrentschuk
European Urology. 20161,009 Citations
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
Marlon Perera, Nathan Papa, Matthew J. Roberts, Michael B. Williams, Cristian Udovicich, Ian Vela, Daniel Christidis, Damien Bolton, Michael S. Hofman, Nathan Lawrentschuk, Declan G. Murphy
European Urology. 2019965 Citations
Related on ScholarIQ
The University of Melbourne
Institution
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Paper
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Paper
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Paper
Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis
Paper
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
Paper